Anti-influenza A virus antibody, and reagent and kit for detecting influenza A virus

Abstract

The invention discloses an antibody for resisting influenza A virus or a reagent and a kit for detecting influenza A virus, and relates to the field of antibodies. The anti-influenza A virus antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of influenza A virus, and has good affinity or activity.

Description

Technical Field

[0001] The present invention relates to the technical field of antibodies, and in particular to an anti-influenza A virus antibody, and a reagent and a kit for detecting influenza A virus. Background Art

[0002] Influenza virus (Flu), also known as influenza virus for short, is a representative species of the Orthomyxoviridae family, including human influenza virus, swine influenza virus, equine influenza virus, avian influenza virus, etc. Human influenza virus can be divided into three types: A, B, and C according to the antigenicity of its nucleoprotein, and is the pathogen of influenza. Influenza virus can cause infection and disease in many animals such as humans, poultry, pigs, horses, and bats. Among them, influenza A virus and influenza B virus can infect humans, mainly causing upper respiratory tract infections, and can also cause lower respiratory tract infections in children and adults, mainly pneumonia. Severe influenza in infants and young children is often accompanied by bronchitis and high fever.

[0003] Influenza A (Flu-A) was successfully isolated in 1933. Its antigens are prone to mutation and can be further divided into subtypes such as H1N1, H3N2, H5N1, and H7N9 (H represents the hemagglutinin of influenza virus, and N represents the neuraminidase of influenza virus). The severity of influenza A virus infection is related to personal immunity. The typical symptoms are mainly chills, persistent high fever, and headache, accompanied by sore throat, cough, and nasal congestion. Generally, there will be systemic symptoms such as body aches and fatigue. Literature reports that the positive detection rate during the epidemic period is 20-40%, while the positive rate in the non-epidemic season is 2-20%. The continuous prevalence of influenza A virus will bring great interference and pressure to people's health, life, and social public epidemic prevention system. It has become one of the main research objects of epidemiology.

[0004] At present, the detection methods for influenza A virus on the market mainly include fluorescent PCR method, immunoassay, and virus isolation, culture and identification. Fluorescent PCR method is to detect the PCR process in real time through fluorescent signals during PCR amplification, for qualitative or quantitative detection purposes. This method is the gold standard for pathogen detection; immunoassay is to detect the target protein through specific binding of antigen and antibody; commonly used methods for virus isolation and culture include chicken embryo inoculation, animal inoculation, tissue (cell) culture, etc., and then observe and analyze the results. Although the fluorescent PCR method has good sensitivity and specificity, its detection window period is short, and it has high requirements for detection personnel. It needs professional skills training and professional instruments and equipment in qualified professional laboratories. Virus isolation, culture and identification detection takes a long time, has high environmental requirements, has a high risk of infection for operators, and has poor culture effects, so its application is very limited. Immunoassay detection reagents target antigens or antibodies in samples, have a fast detection speed and good accuracy, and have low requirements for laboratories and operators. They are generally suitable for grassroots screening such as hospital laboratories and disease control system laboratories. They play a very important role in the initial detection of influenza A, the successful control of outbreaks in hospitals and communities, and the guidance of treatment.

[0005] Currently, the immunoassay reagents for influenza A on the market mainly include enzyme-linked immunosorbent assay (ELISA), colloidal gold immunochromatography, etc. All of the above immunoassay reagents require antibodies against influenza A virus. Therefore, those skilled in the art have a strong demand for anti-influenza A virus antibodies with good performance. Summary of the invention

[0006] The present application provides an antibody or a functional fragment thereof, which provides an important source of raw materials for the detection of influenza A virus and has good activity or affinity.

[0007] In order to achieve the above-mentioned object, according to one aspect of the present invention, an antibody or a functional fragment thereof is provided, wherein the antibody or the functional fragment thereof comprises three complementarity determining regions of a heavy chain variable region having any one of the amino acid sequences of SEQ ID NO: 17, 18, and 19 and three complementarity determining regions of a light chain variable region having the amino acid sequence of SEQ ID NO: 20.

[0008] In order to achieve the above object, according to two aspects of the present invention, an antibody or a functional fragment thereof is provided, wherein the antibody or the functional fragment thereof comprises the following complementary determining regions:

[0009] HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1;

[0010] HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2;

[0011] HCDR3, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 3;

[0012] LCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO:4;

[0013] LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5;

[0014] LCDR3 comprises or consists of the amino acid sequence shown in SEQ ID NO:6.

[0015] In order to achieve the above-mentioned object, according to the third aspect of the present invention, an antibody or a functional fragment thereof is provided, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NO: 17, 18, and 19; and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 20.

[0016] In order to achieve the above-mentioned object, according to the fourth aspect of the present invention, an antibody or a functional fragment thereof is provided, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is shown in any one of SEQ ID NO:21, 22, and 23; and the amino acid sequence of the light chain is shown in SEQ ID NO:24.

[0017] In order to achieve the above object, according to the fifth aspect of the present invention, an antibody conjugate is provided, wherein the antibody conjugate comprises the above antibody or a functional fragment thereof.

[0018] In order to achieve the above object, according to the sixth aspect of the present invention, a reagent or a kit is provided, wherein the reagent or the kit comprises the above antibody or a functional fragment thereof or the above antibody conjugate.

[0019] To achieve the above object, according to a seventh aspect of the present invention, a method for detecting influenza A virus is provided, comprising: a) contacting the above-mentioned antibody or its functional fragment, antibody conjugate, or reagent or kit with influenza A virus in a sample to be detected under conditions sufficient for an antibody / antigen binding reaction to form an immune complex; and b) detecting the presence of the immune complex, wherein the presence of the complex indicates the presence of the influenza A virus in the test sample.

[0020] In order to achieve the above object, according to the eighth aspect of the present invention, a nucleic acid is provided, which encodes the above antibody or a functional fragment thereof.

[0021] In order to achieve the above object, according to the ninth aspect of the present invention, a vector is provided, wherein the vector comprises the above nucleic acid.

[0022] In order to achieve the above object, according to the tenth aspect of the present invention, a cell is provided, wherein the cell comprises the above nucleic acid or vector.

[0023] In order to achieve the above object, according to the eleventh aspect of the present invention, a method for preparing the above antibody or a functional fragment thereof is provided, the method comprising culturing the above cell.

[0024] In order to achieve the above object, according to the twelfth aspect of the present invention, there is provided a use of the above-mentioned antibody or functional fragment thereof, antibody conjugate, reagent or kit in detecting or preparing a product for detecting influenza A virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0026] Figure 1 The figure shows the results of reducing SDS-PAGE of Anti-FLUA 10D9Rmb1 to Rmb3. DETAILED DESCRIPTION

[0027] In the first aspect, an embodiment of the present invention provides an antibody or a functional fragment thereof, wherein the antibody or the functional fragment thereof comprises three complementarity determining regions of a heavy chain variable region having any one of the amino acid sequences SEQ ID NO: 17, 18, and 19 and three complementarity determining regions of a light chain variable region having the amino acid sequence SEQ ID NO: 20.

[0028] In the present invention, the term "antibody" is used in the broadest sense and may include full-length monoclonal antibodies, bispecific or multispecific antibodies, and chimeric antibodies, so long as they exhibit the desired biological activity.

[0029] In the present invention, the term "complementarity determining region", "CDR" or "CDRs" refers to the highly variable region of the heavy and light chains of immunoglobulins, and refers to the region containing one or more or even all of the major amino acid residues that play a role in the binding of an antibody or antigen-binding fragment to its recognized antigen or epitope. In a specific embodiment of the present invention, CDRs refers to the highly variable region of the heavy and light chains of the antibody.

[0030] In the present invention, the heavy chain complementarity determining region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determining region is represented by LCDR, which includes LCDR1, LCDR2 and LCDR3.

[0031] The definition method of CDR is well known in the art, and the CDR definition method includes: Kabat definition, Chothia definition, IMGT definition, Contact definition and AbM definition. As described herein, "Kabat definition" refers to the definition system described by Kabat et al., US Pat. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).

[0032] "Chothia definition" see Chothia et al., J Mol Biol 196:901-917 (1987). There are other CDR definition methods that may not strictly follow one of the above schemes, but will still overlap with at least a portion of the CDR region defined by Kabat, although they may be shortened or extended based on predictions or experimental results of specific residues or residue groups. Exemplary defined CDRs are listed in Table 1 below, and the definitions in different literatures are slightly different. Given the variable region amino acid sequence of an antibody, a person skilled in the art can routinely determine which residues comprise a specific CDR. It should be noted that CDRs defined by other methods not limited to those in Table 1 also fall within the scope of protection of the present disclosure.

[0033] Table 1: CDR Definition 1

[0034]

[0035]

[0036] 1 The numbering of all CDR definitions in Table 1 is based on the Kabat numbering system (see below), with the amino acid numbering on the heavy chain represented by "H+number" and the amino acid numbering on the light chain represented by "L+number". One of ordinary skill in the art can unambiguously map the Kabat numbering system to any variable region sequence without relying on any experimental data other than the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described by Kabat et al., U.S. Patent. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).

[0037] 2 "AbM" as used in Table 1 with a lowercase "b" refers to CDRs defined by Oxford Molecular's "AbM" antibody modeling software.

[0038] 3 If both H35A and H35B are absent, CDR-H1 ends at position 35; if only H35A is present, CDR-H1 ends at position 35A; if both H35A and H35B are present, CDR-H1 ends at position 35B.

[0039] 4 If both H35A and H35B are absent, CDR-H1 ends at position 32; if only H35A is present, CDR-H1 ends at position 33; if both H35A and H35B are present, CDR-H1 ends at position 34.

[0040] 5 If both H35A and H35B are absent, CDR-H1 ends at position 33; if only H35A is present, CDR-H1 ends at position 34; if both H35A and H35B are present, CDR-H1 ends at position 35.

[0041] According to an embodiment of the present invention, the complementarity determining region is defined by any one system of Kabat, Chothia, IMGT, AbM or Contact or a combination of multiple systems.

[0042] In some optional embodiments of the present invention, among the complementary determining regions, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Kabat system.

[0043] In some optional embodiments of the present invention, among the complementary determining regions, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Chothia system.

[0044] In some optional embodiments of the present invention, among the complementary determining regions, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the IMGT system.

[0045] In some optional embodiments of the present invention, among the complementary determining regions, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the AbM system.

[0046] In some optional embodiments of the present invention, among the complementary determining regions, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Contact system.

[0047] In some optional embodiments of the present invention, among the complementary determining regions, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a combination of Kabat, Chothia, IMGT, AbM or Contact systems.

[0048] According to an embodiment of the present invention, the Kabat numbering positions corresponding to the amino acid sequences of the complementary determining regions defined by the Kabat, Chothia, AbM or IMGT systems are as follows:

[0049] CDR Kabat AbM IMGT Chothia HCDR1 H31~H35A H26~H35A H26~H34 H26~H33 HCDR2 H50~H65 H50~H58 H51~H57 H52~H56 HCDR3 H95~H102 H95~H102 H93~H102 H95~H102 LCDR1 L24~L34 L24~L34 L27~L32 L24~L34 LCDR2 L50~L56 L50~L56 L50~L51 L50~L56 LCDR3 L89~L97 L89~L97 L89~L97 L89~L97

[0050] In an optional embodiment, an embodiment of the present invention provides an antibody or a functional fragment thereof, wherein the antibody or the functional fragment thereof comprises the following complementary determining regions:

[0051] HCDR1 comprises or consists of the amino acid sequence shown in SEQ ID NO: 1.

[0052] HCDR2 comprises or consists of the amino acid sequence shown in SEQ ID NO: 2.

[0053] HCDR3 comprises or consists of the amino acid sequence shown in SEQ ID NO: 3.

[0054] LCDR1 comprises or consists of the amino acid sequence shown in SEQ ID NO:4.

[0055] LCDR2 comprises or consists of the amino acid sequence shown in SEQ ID NO:5.

[0056] LCDR3 comprises or consists of the amino acid sequence shown in SEQ ID NO:6.

[0057] In the present invention, the "framework region" or "FR" region includes the heavy chain framework region and the light chain framework region, and refers to the region other than the CDR in the heavy chain variable region and the light chain variable region of the antibody; wherein the heavy chain framework region can be further subdivided into adjacent regions separated by CDR, including HFR1, HFR2, HFR3 and HFR4 framework regions; the light chain framework region can be further subdivided into adjacent regions separated by CDR, including LFR1, LFR2, LFR3 and LFR4 framework regions.

[0058] In the present invention, the heavy chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.

[0059] In an optional embodiment, the antibody or a functional fragment thereof further has at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3 and LFR4;

[0060] The HFR1 comprises / is SEQ ID NO:7 or an amino acid sequence having at least 80% identity thereto;

[0061] The HFR2 comprises / is SEQ ID NO:8 or an amino acid sequence having at least 80% identity thereto;

[0062] The HFR3 comprises / is SEQ ID NO:9 or an amino acid sequence having at least 80% identity thereto;

[0063] The HFR4 comprises / is SEQ ID NO: 10 or an amino acid sequence having at least 80% identity thereto;

[0064] The LFR1 comprises / is SEQ ID NO:11 or an amino acid sequence having at least 80% identity thereto;

[0065] The LFR2 comprises / is SEQ ID NO: 12 or an amino acid sequence having at least 80% identity thereto;

[0066] The LFR3 comprises / is SEQ ID NO: 13 or an amino acid sequence having at least 80% identity thereto;

[0067] The LFR4 comprises / is SEQ ID NO: 14 or an amino acid sequence having at least 80% identity thereto;

[0068] It should be noted that, in other embodiments, the amino acid sequences of the framework regions of the antibodies or functional fragments thereof provided by the present invention may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the above-mentioned corresponding framework regions (SEQ ID NO: 7, 8, 9, 10, 11, 12, 13 or 14).

[0069] In an optional embodiment, the HFR1 comprises / is represented by the amino acid sequence shown in SEQ ID NO:25.

[0070] In an optional embodiment, the HFR3 comprises / is represented by the amino acid sequence shown in SEQ ID NO:26.

[0071] In an optional embodiment, the antibody or its functional fragment has a KD of less than 4.91×10 -10 The affinity of M binds to influenza A virus.

[0072] In an optional embodiment, the antibody or its functional fragment has a KD≤10 -10 M, KD≤10 -11 M or KD≤10 -12 The affinity of M binds to influenza A virus.

[0073] In an optional embodiment, the antibody or its functional fragment has a KD≤2.49×10 -12 The affinity of M binds to influenza A virus.

[0074] There are many methods for determining antibody affinity (KD), which can be divided into thermodynamic detection methods, kinetic detection methods and dynamic equilibrium detection methods according to the detection principle. Among them, thermodynamic detection methods are commonly used, such as isothermal titration calorimetry (ITC); kinetic detection methods are commonly used, such as surface plasmon resonance (SPR) and biomembrane interferometry (BLI); dynamic equilibrium detection methods are commonly used, such as enzyme-linked immunosorbent assay (ELISA).

[0075] In an alternative embodiment, KD is determined using a kinetic assay; optionally, surface plasmon resonance, for example by using a kinetic assay such as Biosensor system of the system.

[0076] In a second aspect, an embodiment of the present invention provides an antibody or a functional fragment thereof, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NO: 17, 18, and 19, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 20.

[0077] In an optional embodiment, the heavy chain variable region and light chain variable region defined in the antibody or functional fragment thereof described in the first aspect or the second aspect are selected from any combination of the following:

[0078] combination Heavy chain variable region Light chain variable region 1 SEQ ID NO:17 SEQ ID NO:20 2 SEQ ID NO:18 SEQ ID NO:20 3 SEQ ID NO:19 SEQ ID NO:20

[0079] In an optional embodiment, the antibody or functional fragment thereof described in the first aspect or the second aspect further comprises a constant region.

[0080] In an alternative embodiment, the constant region includes a heavy chain constant region and / or a light chain constant region.

[0081] In an alternative embodiment, the heavy chain constant region is selected from the heavy chain constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD, and the light chain constant region is selected from the κ type or λ type light chain constant region.

[0082] In an alternative embodiment, the constant region is derived from a species of cow, horse, dairy cow, pig, sheep, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose, turkey, fighting cock or human.

[0083] In an alternative embodiment, the species origin of the constant region is mouse.

[0084] In an optional embodiment, the heavy chain constant region sequence (CH) is as shown in SEQ ID NO:15, and the light chain constant region (CL) sequence is as shown in SEQ ID NO:16.

[0085] It should be noted that, in other embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the above-mentioned constant region (SEQ ID NO: 15 or 16).

[0086] In an optional embodiment, the functional fragment is selected from any one of F(ab')2, Fab', Fab, Fv and scFv of the antibody.

[0087] The functional fragments of the above antibodies usually have the same binding specificity as the antibodies from which they are derived. It is easy for a person skilled in the art to understand based on the contents described in the present invention that the functional fragments of the above antibodies can be obtained by methods such as enzymatic digestion (including pepsin or papain) and / or by chemical reduction to split disulfide bonds. Based on the structure of the complete antibody disclosed in the present invention, a person skilled in the art can easily obtain the above functional fragments.

[0088] The functional fragments of the above antibodies can also be synthesized by recombinant genetic techniques known to those skilled in the art or by, for example, an automatic peptide synthesizer, such as those sold by Applied BioSystems and the like.

[0089] In a third aspect, the present invention provides an antibody or a functional fragment thereof, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is shown in any one of SEQ ID NO:21, 22, and 23, and the amino acid sequence of the light chain is shown in SEQ ID NO:24.

[0090] In an optional embodiment, the antibody or functional fragment thereof described in the first aspect, the second aspect, or the third aspect comprises any combination of the following heavy chains and light chains:

[0091] combination Heavy chain Light chain 1 SEQ ID NO:21 SEQ ID NO:24 2 SEQ ID NO:22 SEQ ID NO:24 3 SEQ ID NO:23 SEQ ID NO:24

[0092] In a fourth aspect, the present invention provides an antibody conjugate, wherein the antibody conjugate comprises the above-mentioned antibody or a functional fragment thereof.

[0093] In an optional embodiment, the above-mentioned antibody conjugate further comprises biotin or a biotin derivative conjugated to the antibody or a functional fragment thereof.

[0094] In an optional embodiment, the antibody conjugate further comprises a label coupled to the antibody or a functional fragment thereof.

[0095] In an optional embodiment, the above-mentioned marker refers to a class of substances with properties that can be directly observed by the naked eye or detected or detected by an instrument, such as luminescence, color development, radioactivity, etc., through which qualitative or quantitative detection of the corresponding target can be achieved.

[0096] In an alternative embodiment, the label includes but is not limited to fluorescent dyes, enzymes, radioactive isotopes, chemiluminescent agents and nanoparticle labels.

[0097] In actual use, those skilled in the art can select a suitable marker according to the detection conditions or actual needs. No matter which marker is used, it belongs to the protection scope of the present invention.

[0098] In an optional embodiment, the fluorescent dye is not limited to fluorescein dyes and their derivatives (for example, including but not limited to fluorescein isothiocyanate (FITC), hydroxyfluorescein (FAM), tetrachlorofluorescein (TET), etc. or their analogs), rhodamine dyes and their derivatives (for example, including but not limited to red rhodamine (RBITC), tetramethylrhodamine (TAMRA), rhodamine B (TRITC), etc. or their analogs), Cy series dyes and their derivatives (for example, including but not limited to Cy2, Cy3, Cy3B, Cy3.5, Cy3.7, Cy3.8, Cy3.9, Cy3.10, Cy3.11, Cy3.12, Cy3.13, Cy3.14, Cy3.15, Cy3.16, Cy3.17, Cy3.18, Cy3.19, Cy3.20, Cy3.21, Cy3.22, Cy3.23, Cy3.24, Cy3.25, Cy3.26, Cy3.27, Cy3.28, Cy3.29, Cy3.30, Cy3.31, Cy3.32, Cy3.33, Cy3.34, Cy3.35, Cy3.36, Cy3.37, Cy3.38, Cy3.39, Cy3.40, Cy3.41, Cy3.42, Cy3.43, Cy3.44, Cy3.45, Cy3.46, Cy3.47, Cy3.48, Cy3.49, Cy3.50, Cy3.51, Cy3.52, Cy3.53, Cy3.54, Cy3.55, Cy3.56, Cy3.57, Cy3.58, Cy3.59, Cy3.59, Cy3.59, Cy3.59, Cy3.59, Cy3.5 y5, Cy5.5, Cy3, etc. or their analogs), Alexa series dyes and their derivatives (for example, including but not limited to AlexaFluor350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750, etc. or their analogs) and protein dyes and their derivatives (for example, including but not limited to phycoerythrin (PE), phycocyanin (PC), allophycocyanin (APC), pre-chlorophyll protein (preCP), etc.).

[0099] In alternative embodiments, the enzyme includes, but is not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and 6-phosphoglucose deoxygenase.

[0100] In an optional embodiment, the radioactive isotopes include but are not limited to 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110mIn, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu and 18F.

[0101] In an optional embodiment, the chemiluminescent reagent includes but is not limited to luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, bipyridine ruthenium and its derivatives, acridinium esters and their derivatives, dioxetanes and their derivatives, lophanes and their derivatives, and peroxyoxalates and their derivatives.

[0102] In an optional embodiment, the nanoparticle markers include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.

[0103] In alternative embodiments, the colloid includes, but is not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex.

[0104] In an alternative embodiment, the colloidal metal includes, but is not limited to, colloidal gold, colloidal silver, and colloidal selenium.

[0105] In an optional embodiment, the colloidal metal is colloidal gold.

[0106] In an optional embodiment, the above-mentioned antibody conjugate further comprises a solid phase carrier coupled to the antibody or a functional fragment thereof.

[0107] In an alternative embodiment, the solid support is selected from microspheres, plates and membranes.

[0108] In an optional embodiment, the solid phase carrier includes but is not limited to magnetic microspheres, plastic microspheres, plastic microparticles, microwell plates, glass, capillaries, nylon and nitrocellulose membranes.

[0109] In a fifth aspect, the present invention provides a reagent or a kit, wherein the reagent or the kit comprises the above-mentioned antibody or a functional fragment thereof or the above-mentioned antibody conjugate.

[0110] As mentioned above, the antibodies or functional fragments thereof in some embodiments or examples of the present invention can effectively bind to influenza A virus, and therefore, the reagents or kits comprising the influenza A virus antibodies or functional fragments thereof can effectively detect influenza A virus qualitatively or quantitatively. The reagents or kits provided by the present invention can be used, for example, for detections involving the use of the specific binding properties of influenza A virus and its antibodies, such as immunoblotting and immunoprecipitation. As mentioned above, the antibodies or functional fragments thereof in some embodiments or examples of the present invention have higher binding activity or affinity with influenza A virus, and therefore, the reagents or kits comprising the antibodies or functional fragments thereof have higher detection sensitivity or specificity.

[0111] In a sixth aspect, the present invention provides a method for detecting influenza A virus, comprising: a) contacting the above-mentioned antibody or its functional fragment, antibody conjugate, reagent or kit with influenza A virus in a sample to be detected under conditions sufficient for an antibody / antigen binding reaction to form an immune complex; and b) detecting the presence of the immune complex, wherein the presence of the complex indicates the presence of the influenza A virus in the test sample;

[0112] In an optional embodiment, the immune complex further comprises a second antibody, which binds to the antibody or a functional fragment thereof.

[0113] In an alternative embodiment, the immune complex further comprises a second antibody, which binds to influenza A virus.

[0114] In a seventh aspect, the present invention provides a nucleic acid molecule encoding the above-mentioned antibody or a functional fragment thereof.

[0115] In an eighth aspect, the present invention provides a vector containing the above-mentioned nucleic acid molecule.

[0116] In a ninth aspect, the present invention provides cells containing the above-mentioned nucleic acid molecule or vector.

[0117] In a tenth aspect, the present invention provides a method for preparing an antibody or a functional fragment thereof, comprising: culturing the cell as described above.

[0118] In an eleventh aspect, the present invention provides use of the above-mentioned antibody or its functional fragment, antibody conjugate, or the above-mentioned reagent or kit in detecting influenza A virus, diagnosing influenza A virus infection, or preparing a product for detecting influenza A virus.

[0119] In a twelfth aspect, the present invention provides a method for diagnosing influenza A virus infection in a subject, comprising: a) contacting the above-mentioned antibody or its functional fragment, antibody conjugate, reagent or kit with a sample from the subject to form an immune complex under conditions sufficient for an antibody / antigen binding reaction to occur; and b) detecting the immune complex.

[0120] Based on the amino acid sequence of the antibody or its functional fragment disclosed in the present invention, those skilled in the art can easily think of using genetic engineering technology or other technologies (chemical synthesis, recombinant expression) to prepare the antibody or its functional fragment, for example, separating and purifying the antibody or its functional fragment from the culture product of a recombinant cell that can recombinantly express the antibody or its functional fragment as described in any of the above items, which is easy to achieve for those skilled in the art. Based on this, no matter what technology is used to prepare the antibody or its functional fragment of the present invention, it belongs to the protection scope of the present invention.

[0121] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0122] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used for the practice or testing of the preparations or unit doses herein, some methods and materials are now described. Unless otherwise stated, the techniques adopted or considered herein are standard methods. Materials, methods and examples are illustrative and non-restrictive only.

[0123] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a skilled artisan. This technique is fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (PCR: The Polymerase Chain Reaction) (Academic Press, Inc., 1987). Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.

[0124] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0125] Example 1 Preparation of Anti-FLUA 10D9 Monoclonal Antibody

[0126] In this example, restriction endonucleases and Prime Star DNA polymerase were purchased from Takara. MagExtractor-RNA extraction kit was purchased from TOYOBO. BD SMART TMThe RACE cDNA Amplification Kit was purchased from Takara. The pMD-18T vector was purchased from Takara. The plasmid extraction kit was purchased from Tiangen. Primer synthesis and gene sequencing were completed by Invitrogen. The hybridoma cell line secreting the Anti-FLUA 10D9 monoclonal antibody was an existing hybridoma cell line prepared in this laboratory and revived for use.

[0127] (1) Antibody gene preparation

[0128] mRNA was extracted from the hybridoma cell line secreting Anti-FLUA 10D9 monoclonal antibody, and the DNA product was obtained by RT-PCR. The product was inserted into the pMD-18T vector after A addition reaction with rTaq DNA polymerase and transformed into DH5α competent cells. After the colonies grew, the Heavy Chain and Light Chain gene clones were taken respectively, and 4 clones of each were sent to a gene sequencing company for sequencing.

[0129] (2) Sequence analysis of the variable region gene of Anti-FLUA 10D9 antibody

[0130] The gene sequences obtained by the above sequencing were placed in the kabat antibody database for analysis, and the VNTI11.5 software was used for analysis to determine that the genes amplified by the heavy chain and light chain primer pairs were correct. Among the gene fragments amplified by the Light Chain, the VL gene sequence was 321 bp, and there was a 57 bp leader peptide sequence in front of it; among the gene fragments amplified by the Heavy Chain primer pair, the VH gene sequence was 348 bp, belonging to the VH1 gene family, and there was a 57 bp leader peptide sequence in front of it.

[0131] (3) Construction of recombinant antibody expression plasmid

[0132] pcDNA TM 3.4 vector is a recombinant antibody eukaryotic expression vector constructed, which has introduced multiple cloning restriction sites such as HindIII, BamHI, and EcoRI, and is named pcDNA3.4A expression vector, hereinafter referred to as 3.4A expression vector; according to the sequencing results of the antibody variable region genes in the above pMD-18T, the VL and VH gene-specific primers of the antibody were designed, with HindIII, EcoRI restriction sites and protective bases at both ends, respectively, and the 0.72kb Light Chain gene fragment and the 1.42kb Heavy Chain gene fragment were amplified by the PCR amplification method.

[0133] The Heavy Chain and Light Chain gene fragments were double-digested with HindIII / EcoRI, and the 3.4A vector was double-digested with HindIII / EcoRI. After the fragments and vectors were purified and recovered, the Heavy Chain gene and the Light Chain gene were respectively connected to the 3.4A expression vector to obtain the recombinant expression plasmids of Heavy Chain and Light Chain, respectively.

[0134] 2. Recombinant Antibody Production

[0135] Resuscitate HEK293 cells in advance and subculture them to 200 ml system to make the cell density reach 3-5×10 6 cells / ml, the cell density reaches the selected antibody concentration and cells, and the cell viability is >95%; the cells are washed by centrifugation and re-dissolved with culture medium, and the cell density is adjusted to 2.9×10 6 cells / ml, wash the cells, and re-dissolve them with culture medium, and use it as a cell diluent. Prepare plasmid DNA and transfection reagent diluents with culture medium respectively. Add the transfection reagent diluent to the plasmid DNA diluent, mix well and let stand at room temperature for 15 minutes; slowly add the mixture to the cell diluent within 1 minute, mix well and take samples to count, record and observe the viability of the cells after transfection, and place them in a 35℃ constant temperature incubator for culture, with a speed of 120rmp and a CO2 content of 8%. Centrifuge and collect samples after 13 days. The centrifuged supernatant was affinity purified using a proteinA affinity chromatography column. Take 6ug layer of purified antibodies for reducing SDS-PAGE, and the electrophoresis is shown in the figure. After reducing SDS-PAGE, two bands are shown, one Mr is 50KD (heavy chain) and the other Mr is 28KD (light chain).

[0136] The obtained antibody was named Anti-FLUA 10D9Rmb1. Anti-FLUA10D9Rmb1 was mutated to obtain a mutant antibody. The sequences of the heavy chain (H) and light chain (L) of the above antibody are shown in the following table:

[0137] Table 2 Antibody sequences

[0138] Antibody Name Heavy chain Light chain Anti-FLUA 10D9 Rmb1 SEQ ID NO:21 SEQ ID NO:24 Anti-FLUA 10D9Rmb2 SEQ ID NO:22 SEQ ID NO:24 Anti-FLUA 10D9Rmb3 SEQ ID NO:23 SEQ ID NO:24

[0139] Example 2 Performance testing of antibodies

[0140] 1. Affinity Analysis

[0141] The purified antibody was diluted in advance, and the influenza A recombinant antigen (obtained from Feipeng Bio) was diluted in a gradient manner; the binding and dissociation curves of the antigen and antibody were tested on the Biacore 8K+ device using a CM5 chip that had been pre-coupled with goat anti-mouse IgG. The instrument automatically fitted the affinity constant, binding rate, and dissociation rate. (KD represents the equilibrium dissociation constant, i.e., affinity constant; ka represents the binding rate; kd represents the dissociation rate)

[0142] Table 3 Affinity data

[0143] Sample name KD ka kd Comparison 4.91E-10 1.27E+06 6.23E-04 Anti-FLUA 10D9 Rmb1 2.43E-12 3.15E+07 7.66E-05 Anti-FLUA 10D9Rmb2 2.38E-12 3.05E+07 7.26E-05 Anti-FLUA 10D9Rmb3 2.49E-12 3.27E+07 8.14E-05

[0144] 2. Activity identification

[0145] The coating solution (main component NaHCO3) was diluted with influenza A recombinant antigen (obtained from Feipeng Bio) to 3ug / ml, 100uL per well, overnight at 4℃; the next day, the washing solution (main component Na2HPO4+Nacl) was used to wash twice and pat dry; the blocking solution (20% BSA+80% PBS) was added, 120uL per well, 37℃, 1h, pat dry; the diluted purified antibody and control antibody were added, 100uL / well, 37℃, 30min; the washing solution was used to wash 5 times and pat dry; the goat anti-mouse IgG-HRP was added, 100uL per well, 37℃, 30min; the washing solution was used to wash 5 times and pat dry; the color developing solution A (50uL / well) and the color developing solution B (50uL / well) were added, 10min; the stop solution was added, 50uL / well; the OD value was read at 450nm (reference 630nm) on the microplate reader.

[0146] Note: Solution A (main ingredients: citric acid + sodium acetate + acetanilide + urea peroxide); Solution B (main ingredients: citric acid

[0147] +EDTA·2Na+TMB+concentrated HCL); stop solution (EDTA·2Na+concentrated H2SO4)

[0148] Table 4 Activity data

[0149] Concentration (ng / ml) 19.531 9.766 4.883 2.441 1.221 0.000 Comparison 0.998 0.602 0.391 0.267 0.167 0.029 Anti-FLUA 10D9 Rmb1 1.503 0.841 0.508 0.334 0.126 0.056 Anti-FLUA 10D9Rmb2 1.513 0.839 0.498 0.350 0.201 0.045 Anti-FLUA 10D9Rmb3 1.506 0.844 0.503 0.322 0.132 0.042

[0150] 3. Stability assessment

[0151] The above antibodies were placed at 4°C (refrigerator), -80°C (refrigerator), and 37°C (constant incubator) for 21 days, and samples were taken for 7 days, 14 days, and 21 days for status observation, and the activity of the 21-day samples was tested. The results showed that there was no obvious protein state change in the antibodies under the three test conditions for 21 days, and the activity did not show a downward trend with the increase of the test temperature, indicating that the above antibodies are stable. Table 5 below shows the OD results of the enzyme immunoassay activity test of the antibody Anti-FLUA10D9Rmb1 for 21 days.

[0152] Table 5 Stability data

[0153] Sample concentration (ng / ml) 19.531 9.766 0.000 4℃, 21-day samples 1.487 0.837 0.014 -80℃, 21 days sample 1.495 0.842 0.002 37℃, 21 days sample 1.506 0.843 0.016

[0154] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

[0155] The partial amino acid sequences involved in this application are as follows:

[0156] Table 6 Amino Acid Sequence Listing

[0157]

[0158]

Claims

1. An antibody or a functional fragment thereof, comprising three complementarity determining regions of a heavy chain variable region having the amino acid sequence of any one of SEQ ID NOs: 17, 18, and 19 and three complementarity determining regions of a light chain variable region having the amino acid sequence of SEQ ID NO:

20.

2. The antibody or functional fragment thereof according to claim 1, characterized in that: The complementarity determining regions are defined by any one of the Kabat, Chothia, IMGT, AbM or Contact systems or a combination of multiple systems.

3. An antibody or a functional fragment thereof, characterized in that: The antibody or its functional fragment comprises the following complementarity determining region: HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1; HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2; HCDR3, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 3; LCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO:4; LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5; LCDR3, which comprises or consists of the amino acid sequence shown in SEQ ID NO:6; Optionally, the antibody or its functional fragment further has at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3 and LFR4; The HFR1 comprises SEQ ID NO:7 or an amino acid sequence having at least 80% identity thereto; The HFR2 comprises SEQ ID NO: 8 or an amino acid sequence having at least 80% identity thereto; The HFR3 comprises SEQ ID NO:9 or an amino acid sequence having at least 80% identity thereto; The HFR4 comprises SEQ ID NO: 10 or an amino acid sequence having at least 80% identity thereto; The LFR1 comprises SEQ ID NO: 11 or an amino acid sequence having at least 80% identity thereto; The LFR2 comprises SEQ ID NO: 12 or an amino acid sequence having at least 80% identity thereto; The LFR3 comprises SEQ ID NO: 13 or an amino acid sequence having at least 80% identity thereto; The LFR4 comprises SEQ ID NO: 14 or an amino acid sequence having at least 80% identity thereto. Alternatively, the antibody or a functional fragment thereof has a KD of less than 4.91×10 -10 The affinity of M binds to influenza A virus.

4. An antibody or a functional fragment thereof, comprising a heavy chain variable region and / or a light chain variable region, characterized in that: The amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NOs: 17, 18, and 19; the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

20.

5. The antibody or functional fragment thereof according to any one of claims 1 to 4, characterized in that: The antibody or its functional fragment further comprises a constant region; Optionally, the constant region includes a heavy chain constant region and / or a light chain constant region; Optionally, the heavy chain constant region is selected from the heavy chain constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; the light chain constant region is selected from the κ type or λ type light chain constant region; Optionally, the species of the constant region is cattle, horse, pig, sheep, goat, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose or human; Optionally, the species origin of the constant region is mouse; Optionally, the heavy chain constant region sequence is as shown in SEQ ID NO: 15 or has at least 80% identity thereto; Optionally, the light chain constant region sequence is as shown in SEQ ID NO: 16 or has at least 80% identity thereto; Optionally, the functional fragment is selected from any one of F(ab')2, Fab', Fab, Fv and scFv of the antibody.

6. An antibody or a functional fragment thereof, comprising a heavy chain and / or a light chain, characterized in that: The amino acid sequence of the heavy chain is shown in any one of SEQ ID NOs: 21, 22, and 23; the amino acid sequence of the light chain is shown in SEQ ID NO:

24.

7. An antibody conjugate, characterized in that: The antibody conjugate comprises the antibody or a functional fragment thereof according to any one of claims 1 to 6; Optionally, the antibody conjugate further comprises biotin or a biotin derivative coupled to the antibody or a functional fragment thereof; Optionally, the antibody conjugate further comprises a label coupled to the antibody or a functional fragment thereof; Optionally, the label is selected from fluorescent dyes, enzymes, radioisotopes, chemiluminescent agents and nanoparticle labels; Optionally, the antibody conjugate further comprises a solid phase carrier coupled to the antibody or a functional fragment thereof; Optionally, the solid support is selected from microspheres, plates and membranes.

8. A reagent or a kit, characterized in that: The reagent or kit comprises the antibody or functional fragment thereof according to any one of claims 1 to 6 or the antibody conjugate according to claim 7.

9. A method for detecting influenza A virus, characterized in that: include: a) contacting the antibody or functional fragment thereof according to any one of claims 1 to 6, the antibody conjugate according to claim 7, or the reagent or kit according to claim 8 with influenza A virus in a sample to be detected under conditions sufficient for an antibody / antigen binding reaction to form an immune complex; and b) detecting the presence of the immune complex, wherein the presence of the complex indicates the presence of the influenza A virus in the test sample; Optionally, the immune complex further comprises a second antibody, which binds to the antibody or a functional fragment thereof; Optionally, the immune complex further comprises a second antibody, which binds to influenza A virus.

10. A nucleic acid, characterized in that It encodes the antibody or its functional fragment according to any one of claims 1 to 6.

11. A carrier, characterized in that It contains the nucleic acid according to claim 10.

12. A cell, characterized in that It contains the nucleic acid according to claim 10 or the vector according to claim 11.

13. A method for preparing the antibody or functional fragment thereof according to any one of claims 1 to 6, comprising: Cultivate the cell of claim 12.

14. Use of the antibody or functional fragment thereof according to any one of claims 1 to 6, the antibody conjugate according to claim 7, or the reagent or kit according to claim 8 in detecting or preparing a product for detecting influenza A virus.

Images